About: Gerasimos Filippatos

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gerasimos Filippatos Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) дослідник (uk) изилдөөчү (ky)
rdfs:label	Gerasimos Filippatos (en) Gerasimos Filippatos (es) Gerasimos Filippatos (nl) Gerasimos Filippatos (sl) Gerasimos Filippatos (sq) Gerasimos Filippatos (ast)
skos:prefLabel	Gerasimos Filippatos (en) Gerasimos Filippatos (es) Gerasimos Filippatos (nl) Gerasimos Filippatos (sl) Gerasimos Filippatos (sq) Gerasimos Filippatos (ast)
name	Gerasimos Filippatos (en) Gerasimos Filippatos (es) Gerasimos Filippatos (nl) Gerasimos Filippatos (sl) Gerasimos Filippatos (sq) Gerasimos Filippatos (ast)
LinkedIn personal profile ID	wds:Q63107352-05f58401-44ea-7f52-0f7f-4df404ab1b03
LinkedIn personal profile ID	gerasimos-filippatos-84796352
instance of	wds:Q63107352-F0C5228A-470A-4B31-9908-5F6B4EF22FA1
instance of	Homo sapiens
occupation	wds:Q63107352-417692c1-4b9c-6712-903a-35551a353956 wds:Q63107352-ecc884e5-4a1e-56d7-4bab-2b1a594b23eb
employer	wds:Q63107352-fc0f7e38-44da-6623-9d0c-1441efea8a9f
CONOR.SI ID	wds:Q63107352-752A91BB-C659-48D9-B581-2C06D91CE9A5
languages spoken, written or signed	wds:Q63107352-C62294D4-454E-47BA-BA4A-B5677381B62E
sex or gender	wds:Q63107352-702376eb-45ab-e911-8253-0eca04988a37
VIAF ID	wds:Q63107352-0235B2B3-ED6F-4CDB-BDC0-F3FB5E9D73F2
educated at	wds:Q63107352-1f0d5e1b-4bdd-bc21-41b2-86c5a41cd965
WorldCat Identities ID (superseded)	wds:Q63107352-B04C19D6-5F51-4C29-A966-79B73BA56CB8
VIAF ID	http://viaf.org/viaf/27146998362718940704
occupation	professor researcher
employer	National and Kapodistrian University of Athens
CONOR.SI ID	137376867
languages spoken, written or signed	English
sex or gender	male
VIAF ID	27146998362718940704
educated at	University of Patras
WorldCat Identities ID (superseded)	viaf-27146998362718940704
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q63107352
is author of	Acute heart failure syndromes: current state and framework for future research Third Universal Definition of Myocardial Infarction Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section Developing therapies for heart failure with preserved ejection fraction: current state and future directions Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Epidemiology of acute heart failure syndromes Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Third Universal Definition of Myocardial Infarction Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice ... Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial 2010 Focused Update of ESC Guidelines on device therapy in heart failure Universal definition of myocardial infarction Third universal definition of myocardial infarction 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu wd:Q28267062 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Soc Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial Depression in coronary artery disease: novel pathophysiologic mechanisms and therapeutic implications Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes 2014 ESC/EACTS Guidelines on myocardial revascularization 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes Successful treatment of heart failure with devices requires collaboration In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study Short-term mortality risk in emergency department acute heart failure Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software